The Pharma Data

MAY 31, 2022

Sandoz, a global leader in generic and biosimilar medicines, today announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity and inequality worldwide. Biosimilars match their respective reference medicine in terms of quality, safety and efficacy.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

DrugBank

AUGUST 9, 2024

Shorter exclusivity periods, driven by patent challenges and the introduction of generic or biosimilar competitors, significantly contribute to declining ROI. When a drug loses patent protection, generic or biosimilar versions can enter the market, leading to a rapid decline in sales for the original brand-name drug. billion by 2030.

Pharmaceuticals 77

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 77

FDA Law Blog: Biosimilars

JULY 10, 2024

Using PGHD can help patients manage their own health and can help sponsors develop endpoints for studying impacts of new treatments that matter to patients. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030.

Clinical Trials 59

Clinical Trials Trials Regulations Treatment 59

The Pharma Data

APRIL 27, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. reflecting lower treatment compliance during the COVID-19 pandemic. First-quarter Fabrazyme ® sales increased 4.7% In the U.S. sales decreased 2.9%

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

FEBRUARY 8, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. Fourth-quarter Fabrazyme ® sales decreased 0.9%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. Fourth-quarter Fabrazyme ® sales decreased 0.9%

Vaccine 52

Vaccine Production FDA Therapies 52